Current blood cancer drug prices not justified, MD Anderson study finds

The costs associated with cancer drug prices have risen dramatically over the past fifteen years, which is of concern to many top oncologists. In a new analysis, researchers at The University of Texas MD Anderson Cancer Center concluded the majority of existing treatments for hematologic, or blood, cancers are currently priced too high to be considered cost-effective in the United States. Their findings are published in the current issue of the journal Cancer.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news